Navigation Links
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Date:1/6/2009

NOVATO, Calif. and SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Following a successful Phase 3 trial, the parties will share equally in all losses and profits. In the United States, BioMarin and La Jolla will jointly commercialize Riquent. In Europe and other territories outside of Asia, BioMarin will be responsible for all commercialization activities.

Jean-Jacques Bienaime, Chief Executive Officer of BioMarin commented, "We are very pleased to become La Jolla Pharmaceutical's partner for Riquent. The development history of Riquent has been long and challenging, but we feel the current study addresses the shortcomings of prior studies and provides the best possible opportunity to demonstrate that Riquent reduces the frequency of renal flares in lupus nephritis patients. The ASPEN Phase 3 study is the largest clinical study ever conducted in lupus nephritis and there is increasing evidence that Riquent targets one of the most important underlying causes of kidney disease in lupus patients, antibodies to double stranded DNA.

Mr. Bienaime continued, "This product opportunity also represents an exceptionally good strategic fit for BioMarin. Lupus nephritis is a serious and potentially fatal orphan disease treated by specialists, primarily nephrologists and rheumatologists, and there are no products specifically approved to treat lupus renal disease. Importantly, if the ASPEN stud
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.; La Jolla Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 2014 Recently, Fadhits.com, a well-known wedding dress ... long graduation dresses to its product line. In ... loyal clients. It wants to bring more benefits for its ... offered at discounted prices, up to 72% off. , As ... working hard. Its online shop is a good place for ...
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... experienced steady growth over the past five years, buoyed ... the agricultural sector's supply management system. “Eggs are a ... a result, per capita egg consumption generally grows in ... IBISWorld Industry Analyst Will McKitterick. Furthermore, demand for new ...
(Date:7/12/2014)... Fresh off their respective performances in the 2014 World Cup, ... at Sun Life Stadium in an international friendly. The World ... stars in the world of football in Colombian and Brazilian ... some of the best talent in the world in early ... team in the world according to the Fédération Internationale de ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... 12, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
Breaking Medicine News(10 mins):Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5
... To be joined by special guests Ringo Starr, Sheryl Crow, ... and Jim JamesTickets go on sale Monday, March 9, at ... Paul McCartney and special guests Ringo Starr, Sheryl Crow, ... Bettye LaVette, and Jim James will perform at the David ...
... CARDIFF, Calif., March 4 Rapid Fire Marketing, (Pink ... Inc., a development stage software firm utilizing the latest ... technology works off a wireless headset that responds to ... power of your own mind. The technology has ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... of BioMarin, will present a company update at the Barclays ... 2009 at 2:30 p.m. ET. Interested parties may access ... investor section of the BioMarin website, www.BMRN.com . ...
... assistant (MCA), featuring touch screen input. The MediSlate was designed ... whether that is a hospital ward, medical clinic or emergency room. ... ... TabletKiosk ®, a leader in mobile computing solutions, today announced ...
... The Johnson Institute has transferred key programs and ... Advocacy under an agreement reached last week by ... )The transfer ensures a continuation of the Johnson ... and possibility of recovery from alcoholism and dependence ...
... will be held Saturday, October 17 at , ... Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced ... Monye Connolly, will serve as the Corporate Chair for its ... The event is scheduled in Atlanta at Centennial ...
Cached Medicine News:Health News:Paul McCartney to Headline Benefit Concert for David Lynch Foundation at Radio City Music Hall on Saturday, April 4 2Health News:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 3Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 4Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 5Health News:Johnson Institute Transfers Key Programs and Products to Hazelden Foundation 2Health News:Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes 2
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation ... of directors has approved a quarterly dividend of $0.275 (27.5 ... is payable on August 1, 2014, to holders of record ... CVS Caremark is dedicated to helping people on ... company in the United States . Through ...
Breaking Medicine Technology:
... 11 Bayer HealthCare Pharmaceuticals announced today that ... U.S. Food and Drug Administration (FDA) for ciprofloxacin dry ... to Pseudomonas aeruginosa in cystic fibrosis (CF) patients. A ... Medicines Agency. Ciprofloxacin DPI is an investigational drug–device combination ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; ... recently introduced Continuum Acetabular Cup System at the ... Continuum Cup combines the best ... Technology, Metasul ® Metal-on-Metal technology, BIOLOX ® delta ...
Cached Medicine Technology:FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 2FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 3FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 4FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 5FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 6FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 7FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 8New Hip Implant Provides Personalized Fit 2New Hip Implant Provides Personalized Fit 3New Hip Implant Provides Personalized Fit 4
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... Marker directly to the biopsy site helps ... performed. ,The MICROMARK® II Tissue Marker is ... for use with the MAMMOTOME Biopsy System. ... site after a biopsy with the MAMMOTOME ...
... A biopsy with the ... an effective, minimally invasive procedure ... patient management.,Using computer-generated images to ... more accurately pinpoint and map ...
Medicine Products: